Epilepsy Drug Sulthiame Shows Promise Against Obstructive Sleep Apnoea
Overview of the Findings
Researchers from Sweden have unveiled promising findings regarding the epilepsy drug Sulthiame. This medication demonstrates potential in combating obstructive sleep apnoea—a serious sleep disorder that affects millions.
Key Results
- Patients taking Sulthiame experienced up to a 40% reduction in symptoms of obstructive sleep apnoea.
- In contrast, those administered a placebo noted minimal improvements.
- This significant finding urges further investigation into the drug's viability for sleep disorder treatments.
Impact on Health Practices
This revelation is a leap forward in exploring alternative treatments for obstructive sleep apnoea. The multifaceted approach to tackling this disorder could lead to enhanced quality of life for numerous patients.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.